No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: Database analyses from Germany and the UK

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 8, 2015, Pages 865-874

  Kowall, Bernd ^a,b   Stang, Andreas ^a,c   Rathmann, Wolfgang ^b   Kostev, Karel ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c BOSTON UNIVERSITY   (United States)

^d IQVIA   (United States)

Author keywords

Cancer; Diabetes mellitus; Insulin; Metformin; Neoplasms; Pharmacoepidemiology; Sulfonylurea

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GERMANY; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; UNITED KINGDOM; VERY ELDERLY; BREAST NEOPLASMS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FACTUAL DATABASE; GREAT BRITAIN; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LUNG NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PROTECTIVE FACTORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84938983934     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3823     Document Type: Article

References (32)

1. DeCensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Canc Prev Res 2010; 3: 1451-1461. doi:10.1158/1940-6207.
2. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813-822. doi:10.1634/theoncologist.2011-0462.
3. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411. doi:10.1371/journal.pone.0033411.
4. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013; 37: 207-218. doi:10.1016/j.canep.2012.12.009.
5. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzaros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013; 62: 922-934. doi:10.1016/j.metabol.2013.01.014.
6. Franciosi M, Lucisano G, Lapice E, Strippoli GFM, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583. doi:10.1371/journal.pone.0071583.
7. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical review. Breast Canc Treat 2012; 135: 639-646. doi:10.1007/s10549-012-2170-x.
8. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes. Diabetes Care 2011; 34: 2323-2328. doi:10.2337/dc11-0512.
9. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2013; 22: 2258-2268. doi:10.1158/1055-9965.
10. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Suresh TC. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 510-519. doi:10.1038/ajg.2013.7.
11. Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol 2014; 180: 11-14. doi:10.1093/aje/kwu124.
12. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891. doi:10.1038/ajg.2013.5.
13. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97: 2347-2353. doi:10.1210/jc.2012-1267.
14. Suissa S, Azoulay L. Metformin and the risk of cancer. Time-related biases in observational studies. Diabetes Care 2012; 35: 2665-2673. doi:10.2337/dc12-0788.
15. Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care 2014; 37: 1786-1788. doi:10.2337/dc14-0500.
16. Yang XL, Ma RCW, So WY, Kong APS, Xu G, Chan JCN. Addressing different biases in analyzing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab 2012; 14: 579-585. doi:10.1111/j.1463-1326.2011.01551.x.
17. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013; 22: 1877-1883. doi:10.1158/1055-9965.EPI-13-0196.
18. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013; 36: 124-129. doi:10.2337/dc12-0740.
19. Mamtani R, Pfanzelter N, Haynes K, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 2014; 37: 1910-1917. doi:10.2337/dc13-1489.
20. Kowall B, Rathmann W, Kostev K. Are sulfonylurea and insulin therapies associated with a larger cancer risk than metformin therapy? A retrospective database analysis. Diabetes Care 2015; 38: 59-65. doi:10.2337/dc14-0977.
21. Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomized clinical trials. Diabetologia 2012; 55: 2593-2603. doi:10.1007/s00125-012-2653-7.
22. Ogdie A, Langan SM, Parkinson J, Dattani H, Kostev K, Gelfand JM. Medical record databases. In Pharmacoepidemiology (5th edn), Strom BL, Kimmel SE, Hennessy S (eds.). Wiley-Blackwell: Oxford, 2012; 224-243. doi:10.1002/9781119959946.ch15.
23. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009; 47: 617-626.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
25. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2007; 167: 492-499.
26. Yang X, Kong APS, Oy Luk A, et al. Validation of methods to control for immortal time bias in a pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes. J Epidemiol 2014; 24: 267-273.
27. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841. doi:10.1056/NEJMoa1008862.
28. Van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55: 654-665. doi:10.1007/s00125-011-2390-3.
29. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 280-286. doi:10.1158/1055-9965.EPI-11-0992-T.
30. Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like in intention-to-treat trial. Diabetes Care 2014; 37: 2522-2532. doi:10.2337/dc14-0584.
31. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 349-357. doi:10.1111/dom.12036.
32. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008; 105: 4283-4288. doi:10.1073/pnas.0712345105.